Browse News
Filter News
Found 804,952 articles
-
Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion.
-
Orchard Therapeutics on Monday secured the FDA’s first approval for an autologous gene therapy to treat the rare metabolic disease metachromatic leukodystrophy in children.
-
To help support the launch of Lyfgenia, bluebird bio on Monday entered into a five-year term loan deal with Hercules Capital that will extend the biotech’s cash runway through the first quarter of 2026.
-
An appellate court sided with Regeneron versus Novartis on Monday, agreeing that anti-VEGF pre-filled syringes constitute a distinct market than those sold in vials. The case involves Regeneron’s Eylea and Novartis’ Lucentis eye treatments.
-
BioSpace's 2024 Salary Report explores the average salaries and salary trends of life sciences professionals.
-
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
3/19/2024
Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® in the United Kingdom.
-
Brain Recordings in People Before Surgery Reveal How All Minds Plan What to Say Prior to Speaking
3/19/2024
A new study in people undergoing surgery to treat seizures related to epilepsy shows that pauses in speech reveal information about how people's brains plan and produce speech.
-
CB Scientific, Inc. Concludes its Annual Meeting of Stockholders
3/19/2024
CB Scientific, Inc., a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced that the company successfully concluded its Annual Meeting of Stockholders on Thursday, March 14, 2024 as planned.
-
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
3/19/2024
Biogen Canada Inc. announced that Health Canada has accepted for review a New Drug Submission for tofersen for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene.
-
Cytovale's Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
3/19/2024
Cytovale® announced new data that demonstrates how its IntelliSep® test reduced cost of care and improved efficiency of sepsis care for a large U.S. academic center.
-
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
3/19/2024
CSL Vifor announced that Health Canada has authorized Ferinject for the intravenous treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III* to improve exercise capacity.
-
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
3/19/2024
Conduit Pharmaceuticals Inc. announced the appointment of Dr. Joanne Holland as Chief Scientific Officer.
-
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
3/19/2024
Revive Therapeutics Ltd. announced that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.
-
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
3/19/2024
Tourmaline Bio, Inc. announced its financial results for the fourth quarter and year ended December 31, 2023 and outlined recent business highlights.
-
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
3/19/2024
Enveric Biosciences is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases.
-
LSL Pharma Group Secures $6.44 Million as the First Closing of Concurrent Non-Brokered Private Placements
3/19/2024
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, announced the closing on March 18, 2024 of non-brokered private placements for $6.44 million representing the first closing of the $8.0 million combined financings announced on March 7, 2024.
-
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
3/19/2024
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates.
-
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
3/19/2024
Axsome Therapeutics, Inc. announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder.
-
PECA Labs Receives Expanded CE Mark for exGraft Family of Vascular Grafts, Allowing for Expandability Designed to Match Growth or Help Avoid Restenosis
3/19/2024
PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, has received an additional CE Mark for its exGraft family of vascular grafts, expanding its on-label use.
-
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
3/19/2024
Century Therapeutics announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.